Published in Vaccine Weekly, March 13th, 1995
Clinical trials with Oka/Merck varicella vaccine have been ongoing in the United States since 1981. Reinfection or breakthrough illness has occurred in approximately 5 percent of vaccinees and has generally been mild in comparison with natural infection. The incidence of reinfection correlates inversely with the antibody titers documented six weeks after vaccination; this correlation suggests that protection might be even more complete and longer lasting if higher antibody...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.